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Objectives: Since the introduction of non-vitamin-K-antagonist oral anticoagu-
lants (OACs), an additional option for stroke prevention in patients with atrial fibril-
lation (AF) compared to vitamin-K-antagonists (VKAs) is available. The objective 
of this study was to assess patients’ preferences regarding the attributes of these 
different treatment options. MethOds: We conducted a multicenter study among 
randomly selected physicians who were asked to recruit AF patients. Patients’ 
preferences were assessed by computer-assisted telephone interviews. We used a 
Discrete-Choice-Experiment (DCE) with four treatment dependent attributes (need 
of bridging: yes/no, interactions with food/nutrition: yes/no, need of INR controls/
dose adjustment: yes/no, frequency of intake: once/twice daily) and one compara-
tor attribute (distance to practitioner: < 1km/> 15km). Preferences measured in the 
interviews were analyzed descriptively and based on a conditional logistic regres-
sion model. Results: A total of 140 AF patients (age: 74.0±8.5 years; 57.0% male; 
mean CHA2DS2-VASc: 6.1±1.1; current medication: 27.1% rivaroxaban, 71.4% VKA, 
1.4% other) could be interviewed. Regardless of type of medication, patients signifi-
cantly preferred the attributes’ level (in order of patients’ importance) “once daily” 
for “frequency of intake” (binary-coded: once = 1 vs. twice = 0; Coefficient = 0.954; 
p< 0.001), “no” for “interaction with food/nutrition” (yes vs. no; -0.842; p< 0.001), “no” 
for “bridging necessary” (yes vs. no; -0.656; p< 0.001) and “≤ 1 km” for “distance to 
practitioner” (≤ 1 km vs. > 15 km; 0.644; p< 0.001). However, for the attribute “need of 
INR controls/dose adjustment” (yes vs. no; 0.020; p= 0.808) no significant preference 
in favour of one of the options are shown. cOnclusiOns: In our analyses, “once 
daily frequency of intake” was the most important attribute for patients’ choice 
followed by “no interactions with food/nutrition” and “no bridging necessary”. Thus, 
patients with AF seem to prefer treatment options which are easier to administer.
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Objectives: There are few studies in Spain about outcomes at 1-year in terms of 
health-related quality of life (HRQoL) in patients hospitalized by heart failure (HF). 
The main objective of the present study was to evaluate changes in HRQoL from 
baseline to 1-year post discharge in patients with HF through two questionnaires, 
SF-12 and Minnesota Living with Heart Failure questionnaire (MLHFQ). MethOds: 
This has been a prospective study with 502 patients admitted by HF in Basque 
Country (Spain). Patients completed questionnaires during their hospitalization and 
at 1-year. The MLHFQ is a specific instrument which has 21 items with an overall 
scale, physical (8 items) and emotional (5 items) subscales. MlhFQ items are scoring 
from 0 (best) to 5 (worst). Total score ranges from 0 to 105, physical domain from 
0 to 40 and emotional from 0 to 25. SF-12 has two dimensions, Physical Summary 
Score (PCS) and Mental Summary Score (MSC) which scores range from 0 (worst) 
to 100 (best). We have used general linear model to study gains in each dimension 
adjusted by baseline score, age, gender and hospital readmissions in the previous 
6 months. Results: Mean age was 76.7 (SD= 10.4), there were a 56.1% of men and 
20.3% of readmissions in the previous six months. Regarding both questionnaires 
and dimensions, baseline status influence in gains, the worse the baseline the more 
the gains. Likewise men have greater gains and patients readmitted lower in all 
domains. Age has an influence in MLHFQ physical domain and PCS. cOnclusiOns: 
Adjusted by baseline score and readmissions, men have greater improvements in 
all domains of MLHFQ and SF-12. On the other hand, the younger the patients the 
higher the improvement is, in physical domains however age does not have any 
influence in psychological domains.
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Objectives: To identify and summarize the key characteristics, strengths, and 
weaknesses of available patient-reported outcome (PRO) measures assessing treat-
ment satisfaction and health-related quality of life (HRQOL) related to anticoagula-
tion therapy in patients with atrial fibrillation, including evaluating how well the 
measures meet current regulatory guidance requirements in Europe and the United 
States. MethOds: Publications describing the development, validation, or use of 
PRO instruments in patients using anticoagulant therapy were identified through 
a comprehensive literature review. Several sources (PubMed, Patient-Reported 
Outcome and Quality of Life Instruments Database [PROQOLID], and ClinicalTrials. 
org) were reviewed to identify instruments. The development process and meas-
urement properties (internal consistency and test-retest reliability, convergent and 
divergent construct validity, known-groups validity, and responsiveness) of the iden-
tified instruments were compared. Results: Five measures assessing anticoagu-
self-reported adherence results and any of the 4 factor scores. cOnclusiOns: 
This study provides BMQ factor scores for urban black HTN patients and insight 
into how experiences of patient’s parents can be used to target increased per-
ception of anti-hypertensive medication necessity and reduce patient-specific 
medication harm concerns.
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Objectives: To investigate the living and employment situation of patients after 
stroke, and examine whether this differs by degree of disability. MethOds: We 
conducted an observational retrospective study among 569 post-stroke patients 
and examined changes in employment and living situation. The investigational 
period was divided into 3 intervals: < 3,3-6 and > 6 months after stroke. All patients 
had their mRS (modified Rankin Score, ranging from 0 full health to 5 severely 
dependent) measured at 3 months after stroke, plus an additional mRS assessment 
if their stroke was more than 6 months ago. Patients were recruited in 10 regional 
and university hospitals across Belgium using a convenience sample stratified by 
mRS. Results: Before their stroke the majority of patients lived at home (99%) 
despite the fact that 13% had a previous stroke. At 3 months after stroke an associa-
tion was found between the time spent in an inpatient care facility (hospital, reha-
bilitation facility, nursing home) and the mRS (p< 0.0001 Weibull survival analysis, 
average inpatients days were 9.2, 14.1, 27.7, 53.4, 67.0 and 73.4 for mRS 0-5 respec-
tively). Between 3 and 6 months after stroke on average 7% of patients were staying 
in a rehabilitation facility and 5% in a nursing home; these were mostly patients 
with mRS > = 3. After six months all patients returned home, except patients with 
mRS4 (36% home) and mRS5 (38% home). Before stroke 70% of patients were retired; 
in those working before their stroke, 16-20% patients in mRS categories 0-2 were 
working again compared to none in mRS category 3-5, of which 14% took early 
retirement or leave of absence. cOnclusiOns: Experiencing a mild stroke will 
not affect the patient’s employment and living situation beyond the short term; 
however suffering a severe stroke is likely to lead to significant changes in place of 
residence and occupation.
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Objectives: Evaluate validity and reliability of the UISESS-B oral health ques-
tionnaire in a Mexican diabetic, systemic hypertension and obese patients in the 
primary health care level. MethOds: Were studied 105 subjects with diabetes, 
systemic hypertension and/or over-weigh-obesity in the context of a diabetic’s 
control group in the Instituto Mexicano del Seguro Social. Was applied an oral 
health questionnaire named UISESS-B previously validated. The instrument is 
divided in three main areas: oral health care habits, oral health and nutrition 
related habits, and oral health care related symptoms and signs. ResultsConstruct 
validity was confirmed by the correct compilation of the items included in the 
two main constructs: habits and perceptions each one including specific multi-
item questionnaires (correlation coefficients ranged from 0.30 to 0.80, P>0.001); 
the reliability was confirmed by the internal consistency (Cronbach alpha: 0.55 
for the construct habits and 0.71 for the construct perceptions). cOnclusiOns: 
The UISESS-B questionnaire shows significant validity and reliability, suggesting 
its use as an instrument useful to be used as a patient reported outcome in oral 
health in patients with chronic diseases.
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Objectives: Many years ago, cardiologists developed on the basis of the 
Framingham study an “arterial age” which is very useful to sensitize patients to their 
cardiovascular risk. The purpose of the study was to develop a “venous age” to make 
people more aware of their venous disease and to better adhere to lifestyle improve-
ment and venous disease treatments. MethOds: The score calculation was based 
on an international epidemiological study conducted in 24 countries in the daily 
practice or general practitioners. The data base included patients with or without 
venous disease, whatever the reason for which they were consulting and whatever 
the level of their venous disease which was systematically described according the 
elements of the international CEAP classification. Results: The study covers 124 
235 patients aged of 52 among whom 69.4% were female. Among them 18.8% had no 
sign of venous disease (C0), 22.9% had only functional symptoms (C0s), 40.6% had 
Telangiectasies or reticular veins, 34.8% varicose, 24.9% edema, 14.0% skin changes, 
7.3 Healed ulcers and 4.3% active ulcers. The statistical analysis has determined 
the number of years which must be added to the real age to get the “venous age” 
by comparison of the age of somebody who has no venous functional symptoms 
or physical signs. The results provide that number for women and men according 
the different venous symptoms and sign they present. cOnclusiOns: This first 
attempt of creating a “venous age” will be certainly improved in the next future, 
using more complex analysis based on risk factors or other criteria, but it seems 
already efficient to make people aware of their venous risk and to better adhere to 
lifestyle improvement and venous disease treatments.
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Objectives: This study aimed to determine anti-coagulant treatment patterns and 
stroke- and bleeding-related risk factors and to evaluate quality of life (QoL) in non-
valvular atrial fibrillation (NVAF) patients. MethOds: This multicenter (12-centers), 
observational study included ≥ 18 year-old patients (n= 213) diagnosed with NVAF. 
CHADS2, CHA2DS2-VASc, HAS-BLED scores and EQ-5D scale were used to assess risk 
factors and QoL and clinical features were recorded at baseline, and 6th and 12th 
months. Results: The rate of adverse events was 64.7%, major bleeding was 10.8%, 
stroke was 5.9%, and hospitalization was 25.5% in one-year follow-up. The patients’ 
treatment patterns were grouped as warfarin, new oral anti-coagulant (NOAC) (dabi-
gatran, rivaroxaban), and antiplatelet agents (AA) (acetylsalicylic acid, clopidogrel). 
Patient numbers for the groups at baseline, and 6th and 12th months, respectively, 
were 92, 74, 41 for warfarin, 2, 13, 14 for NOAC, and 39, 29, 26 for AA. The distribution 
of patients in the warfarin, NOAC, and AA groups regarding CHADS2≥ 2 was 53.8% 
(n= 49), 50% (n= 1), and 63.2% (n= 24), respectively; regarding CHA2DS2-VASc≥ 2 was 
86.8% (n= 79), 50% (n= 1), and 89.5% (n= 34), respectively; and regarding HAS-BLED≥ 3 
(high bleeding risk) was 23.1% (n= 21), 0% (n= 0), and 18.4% (n= 7), respectively. EQ-5D 
scale scores were 0.85±0.12 and 0.76±0.13 at baseline and 0.67±0.29 and 0.62±0.37 at 
12th month for the warfarin and AA groups, respectively; the decrease was significant 
in the warfarin group (p= 0.002) but not in the AA group (p= 0.249). The mortality rates 
of the patients in the warfarin, NOAC, and AA groups in one-year follow-up were 7.6%, 
0.0%, and 10.3%, respectively. cOnclusiOns: Our study has demonstrated that a 
significant number of patients who should be on oral anticoagulants are still treated 
with AA and the negative effects of warfarin on QoL of NVAF patients as compared 
to AA. More data is needed with head-to-head comparison of warfarin and NOAC.
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Objectives: 2579 permanent cardiac pacemakers (PCPM) were implanted in 
Slovakia in the year 2012, 532 reimplantations were utilised in 475 resp. 98 per 
1000000 inhabitants. Up to now in the Slovak Republic there was not realised the 
study oriented on OoL in the patients with this treatment. MethOds: 100 patients 
with PCMK were studied, women 58, men 42. The average age was 66.47, duration of 
illness – 6.93 y. 57 patients were married, 31 divorced or a widower, widow, single - 
12.39 patients had sick sinus syndrome (SSS). 22 - AV blockade II, 23 - AV blockade III, 
16 - brady form of atrial fibrillation. QoL was evaluated by standardised instrument 
and so Quality of Life Index Cardiac Version – IV). Four domains were examined: 
health and functional state, mental and spiritual state, family relations. Finally, the 
total QoL was discovered, too. Kruskall Wallis Anova Test and Mann-Whitney Tests 
were used to verify the statistical significance. Results: None of rhythm disor-
ders and the duration of illness had impact on QoL. The smallest QoL occurred in 
health and functional state, the highest QoL occurred in family relations. In the last 
one (family relations) there was significant difference in comparison to the other 
domains (p ≤ 0,029), and specifically in the group of married patients. The age had 
negative significant correlation on QoL (p ≤ 0,027). Women had significant lower 
QoL in the social and economical fields. cOnclusiOns: PCPM has a certain impact 
on QoL. The knowledge about the differences in the field of family state and in age 
gives the incentive to take more attention to older, divorced, widower/widows and 
single patients and try to realise relevant psychological interventions.
PCV138
The eValuaTiOn Of The healTh relaTed QualiTy Of life amOng adulTs 
WiTh hyPerTensiOn
Paczkowska A., Nowakowska E., Koligat D., Bryl W., Hoffmann K.
Poznan University of Medical Sciences, Poznan, Poland
Objectives: The aim of the study was a subjective evaluation of the quality of life 
among adults with diagnosed and treated hypertension. The paper also identifies 
social and clinical factors significantly influencing the quality of life of respondents.  
MethOds: 112 people took part in the study (38 women and 78 men), aged between 19 
and 65 years old – in all cases hypertension was diagnosed and treated in a particular 
health care centre. As a main study tool a questionnaire WHOQOL-BREF in a Polish 
version was applied. In addition, in order to evaluate the social and clinical factors that 
influence the quality of life participants were asked to fill anonymous questionnaire 
prepared specially for this study. Results: The results of the conducted studies indi-
cated that people suffering from hypertension experience remarkably lower quality 
of life comparing to healthy people. Considerable discrepancies in terms of the qual-
ity of life were visible in physical and psychological domains of the WHOQOL-BREF 
questionnaire. It has been assumed that the quality of life of patients with hyper-
tension is determined by both social (age, gender, education, economic status), and 
clinical (level of blood pressure, weight, the type of hypertensive therapy, the presence 
of coexisting diseases). cOnclusiOns: Chronic diseases, including hypertension, 
distinctively affect the quality of life of patients. The quality of life of patients with 
hypertension is determined by numerous social and clinical factors. Thus, there is a 
need to consider the problem of hypertension and its treatment among adult people 
multidisciplinary – in order to improve their lives.
PCV139
TreaTmenT saTisfaCTiOn in PaTienTs WiTh VenOus ThrOmbOembOlism 
as measured WiTh PaCT-Q2: Prefer in VTe regisTry
Willich S.N.1, Bauersachs R.2, Gitt A.K.3, Mismetti P.4, Monreal M.5, Wolf W.P.6, Agnelli G.7, 
Cohen A.T.8
1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Max-Ratschow-Klinik für Angiologie, 
Gefäßzentrum Klinikum Darmstadt GmbH, Darmstadt, Germany, 3Herzzentrum Ludwigshafen, 
lation-related PROs were identified: 1) Sawicki questionnaire (assesses treatment 
satisfaction and HRQOL); 2) Perception of Anticoagulant Treatment Questionnaire 
(PACT-Q); 3) Duke Anticoagulation Satisfaction Scale (DASS); 4) Anti-Clot Treatment 
Scale (ACTS) (based on the DASS conceptual model); and 5) Deep Venous Thrombosis 
Quality of Life (DVTQOL) (assesses HRQOL outcomes related to a primary event of 
DVT and includes items assessing anticoagulation burden). All of the measures 
except the Sawicki questionnaire involved anticoagulated patients in the process 
of item generation and refinement. The ACTS and the DASS exhibited the strongest 
measurement properties. To a limited degree, the ACTS, DASS, and Sawicki question-
naire have demonstrated responsiveness in clinical trial settings. cOnclusiOns: 
Although some of the identified measures have shown responsiveness in clinical 
trials, this review concluded that no existing measure appears likely to support an 
FDA or EMA PRO label claim in anticoagulation-related treatment satisfaction or 
HRQOL. However, concepts related to anticoagulation treatment satisfaction and 
HRQOL are important to patients and should be included in clinical trials, particu-
larly as the burdens and benefits of anticoagulants evolve over time.
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Objectives: To compare the health utility of Acute Coronary Syndrome (ACS) 
patients from an Asian population at baseline admission and 12 months post-ACS. 
Secondary objectives were to investigate the factors that affect health utility and 
the impact of using local versus UK tariffs in the analysis. MethOds: Primary 
data was obtained from ACS patients who were admitted to a tertiary-care, general 
hospital in Malaysia and agreed to participate in the study. The quality of life (QOL) 
of ACS patients was elicited using validated language versions of the EQ-5D (three 
severity level) patient reported outcome instrument. QOL data was collected at 
baseline during initial admission for ACS and at 12-months post-admission. Patient 
demographic and clinical data were extracted from medical records. Health utility 
scores were calculated using EQ-5D utility tariffs from Malaysia and the UK popula-
tion tariff. Results: A total of 112 subjects were recruited into the study of which 
104 were used in the primary analysis. Mean age of patients in the analysis dataset 
was 56.1 years, 88% were male and duration of admission was 6.3 days. Calculated 
by Malaysian tariff weights, health utility was 0.75 during initial admission, increas-
ing to 0.82 after 12 months (p= 0.012). Among the statistically significant factors 
associated with lower baseline utility were diagnosis of NSTEMI/unstable angina 
compared to STEMI (p= 0.045), and female sex (p= 0.038). Utilities calculated using the 
Malaysian tariff was consistently higher than those calculated using the UK tariff. 
ACS utility at baseline was 0.75 and 0.62 (p< 0.001) while utility after 12 months was 
0.82 and 0.72 (p< 0.001) respectively. cOnclusiOns: This study investigates several 
factors that may impact the QOL outcomes of Malaysian ACS patients. It also found 
significant differences in utility values calculated by Malaysian and UK tariffs, which 
indicate that the use of local tariffs is more appropriate.
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Objectives: A secondary objective of a phase-III study spanning 54 weeks was to 
measure changes in the health-related quality of life (HRQoL) of 2,690 patients ≥ 18 
years of age with moderate-to-severe hypertension who ended up receiving one of 
six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) using the 
MINICHAL and EQ5D instruments. MethOds: Descriptive statistics were used to 
measure blood pressure and HRQoL scores over the study period. Analysis of covari-
ance (ANCOVA) was used to identify those factors (i.e. age, sex etc.) that could pos-
sibly have influenced HRQoL. Linear regression was used to assess the relationship 
between changes in blood pressure and HRQoL scores. Results: At the study start 
90.8% of patients had Grade 2 or 3 hypertension, but at the study end 91.9% had nor-
mal/high-normal BP. Patients’ baseline MINICHAL mood and somatic domains scores 
were 5.5 and 2.6. Over the study period HRQoL improved as both MINICHAL scores 
decreased by 31-33%. Patients’ baseline EQ5D index and VAS score was 0.9 and 73.4 
respectively, increasing by 6% and 12% over the study period. Patients’ QALY gain over 
the 54 weeks study period was estimated to be 0.029 QALYs. Linear regression was 
unable to detect any correlation between the changes in blood pressure and HRQoL 
scores. The ANCOVA model showed that changes in patients’ HRQoL was likely to 
have been influenced by patients’ grade of hypertension at baseline, the amount of 
concomitant medication (“pill burden”) and patients’ antihypertensive treatment in 
the last 26 weeks of the study. cOnclusiOns: OLM/AML/HCTZ reduced blood pres-
sure and significantly increased blood pressure control whilst improving patients’ 
HRQoL. Reducing patients’ pill burden is likely to increase adherence to treatment 
and improve blood pressure control. Hence, when prescribing antihypertensive agents 
physicians should consider the impact that pill burden has on adherence to treat-
ment, achieving blood pressure control and patients’ HRQoL.
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